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Abstract 
Chronic Myeloid Leukemia is the first malignant disorder with a specific genetic abnormality in the background. Known as 
a disease with an inexorable progression to acute leukemia for many years, its natural history has been dramatically improved by 
the use of tyrosine kinase inhibitors (TKI). They represent the first molecular targeted therapy addressed to a neoplastic disorder. 
From these new classes of drugs, Imatinib was the first drug ever used, and it remains the standard therapy for patients in chronic 
phase with CML, having a global survival of 86%, for 7 years. The 2nd generation of TKI (Dasatinib, Nilotinib) is indicated for the 
patients who are refractory or intolerant to Imatinib. The other TKI have good promises to be efficient on the mutations of BCR-ABL 
transcript, especially to non-responsive T315I mutation. 
The new era of molecular target therapy is a new hope of life for all cancer patients. 
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Background 
Chronic Myeloid Leukemia (CML) is a 
myeloproliferative disorder due to a clonal pluripotent 
stem cell disorder. Wirchow and Binnet described it for 
the first time in 1845 and it was the first malignant disease 
with a genetic marker involved in its etiology. The genetic 
marker is represented by the Philadelphia chromosome 
(Ph) described in 1960 and the results from a reciprocal 
exchange of material between two chromosomes: 9 and 
22 chromosomes, t(9;22)(q34;q11) [1]. 
The Philadelphia chromosome is identified in over 
95% of patients with CML and represents the genetic hallmark 
of CML; the molecular marker is the presence of BCR-ABL 
fusion gene – mandatory for positive diagnosis [2]. 
Pathogeny 
CML is a hematopoietic stem cell disorder, 
developed from the translocation t(9;22)(q34;q11), known as 
Philadelphia chromosome. This translocation produces the 
juxtaposition of ABL gene on chromosome 9 with BCR gene 
from chromosome 22, resulting in the fusion gene, which 
encodes the BCR-ABL transcript and the fusion proteins with 
abnormal tyrosine kinase activity. [2] (Figure 1). 
 CML pathogeny is well known, and it has been studied in 
detail at a molecular level, but the mechanism of 
translocation is not very well understood. Exposure to 
radiation is suggested as a possible cause, because of 
the increase in incidence after the nuclear explosions 
from Hiroshima and Nagasaki [3]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Graphical representation of BCR-ABL transcripts 
resulting from the translocation t(9;22). 
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BCR-ABL fusion gene produced from BCR and 
ABL genes, usually encoded the protein p210 with 
tyrosine kinase activity. This activity is responsible for the 
proliferation mechanisms in CML. There are two fusion 
genes, which are described as having different molecular 
weight, p190, specific for acute lymphoblastic leukemia, 
and rarely, p230. [3] 
Diagnosis 
In most cases, CML is diagnosed by a specific 
hematological picture of peripheral blood, with excessive 
granulopoiesis on left shift. Diagnosis criteria established 
by last ESMO recommendations are: 
•  Leucocytosis +/- Thrombocytosis (150-
450 x 109/l) 
•  Left shift of differential – to myeloblasts 
•  Basophils < 20% 
•  Splenomegaly (>50%) 
•  Ph1 chromosome (t(9;22)/ BCR-ABL 
fusion gene in peripheral blood/bone marrow detected by 
cytogenetic/PCR analysis 
In about 5% of cases, Ph1 chromosome is 
absent, and the diagnosis is confirmed by BCR-ABL 
transcript detection through FISH or PCR. 
Treatment 
For many years, the specific treatment for CML 
consisted of cytoreduction, and the combination between 
immunomodulatory (interpheron-alpha) and Ara-C 
represented an important change in CML patients’ 
prognosis in the middle of ’90s (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tyrosine kinase inhibitors discovery at the end of 
the millennium represented a crucial moment in the 
treatment of CML. The purpose of the treatment in CML is 
to obtain three complete responses: hematological, 
cytogenetically, molecular (Figure 3). 
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Fig. 3 Graphical representation of treatment purpose in 
CML. 
 
The mechanism of action of TKI is accomplished 
by blocking the locus with a TK function at the BCR-ABL 
transcript, thus representing the first treatment, which 
specifically inhibits a genetic alteration as the etiology of 
malignant process. 
TKI are classified according to the target in BCR-
ABL transcript, as it follows: 
 
•  abl TK inhibitors 
o  Imatinib (Novartis) 
o  Nilotinib (AMN107, Novartis) 
•  Dual Abl/Src inhibitors 
o  Dasatinib (BMS 254825, Bristol-Myers       
Squibb) 
o  SKI-606 - ‘bosutinib’ (Wyeth) 
o  AP23464 (Ariad Pharmaceuticals) 
o  AZD0530 (Astra-Zeneca) 
•  Dual Abl/Lyn inhibitor 
o  NS-187 (INNO-406) (Nippon-Shinyaku) 
•  Non-ATP-binding inhibitors active against T315I 
o  ON 012380 (Onconova) 
o  VX-680 (Aurora kinase inhibitor) Æ Merck 
0457 - T315I 
o  SGX-70430 (SGX Pharma)  
o  GNF-2 (Genomics Novartis Foundation) 
 
Imatinib was the first inhibitor discovered for 
tyrosine kinase and it remains the standard treatment in 
CML. It is an ABL specific tyrosine kinase inhibitor, which 
inhibits the proliferation of CML cell lines by inhibiting ATP 
binding at ABL tyrosine kinase. 
Fig. 2 Graphical representation of treatment options in 
CML 
 
Many comparative studies have been reported 
since the beginning of the use of Imatinib in patients with 
CML. They compared the efficacy of Imatinib with other 
therapies such as Interferon alpha, cytarabine, stem cell 
transplantation (Table 1). 
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  Table 1 Comparative studies with Imatinib in CML  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The  IRIS study compared the efficacy of 
Imatinib (in doses of 400, 600, 800 mg/day) to α-INF + 
ARA-C, in a follow-up period of 6-7 years. 553 patients 
were randomized in each branch. The IRIS study 
estimated adverse reactions rates, complete 
hematological, cytogenetic and molecular responses 
rates, progression free survival to accelerated phase or 
blast crisis CML [4]. 
The conclusions of the IRIS study were the 
following: 82% of Imatinib treated patients achieved 
complete cytogenetic response; only 17% of them 
relapsed and 3% progressed to accelerated phase / 
blastic crisis; 2% resulted in death. There was a long-term 
response, and annual risk of progression is decreasing in 
time. 
The molecular response rate was significant, and 
survival for 7 years was of 86%, superior to any other 
therapy. 
Another important trial was SPIRIT, from the 
French Working Group in CML, on a group of 636 
patients, on one-year follow-up period. The study 
compares the response to Imatinib in doses of 400 mg 
versus 600 mg versus Imatinib and another therapy (Ara-
C or IFN-alpha). 
The common conclusion of these studies was 
that Imatinib alone or in combination with other therapies 
is the first line treatment in patients with chronic phase 
CML. 
 
Resistance to Imatinib 
There is a category of CML patients, who do not 
respond to standard dose of Imatinib, or, they relapse 
after an initial response. Those patients are considered 
resistant to Imatinib. Drug resistance is associated with 
the reactivation of BCR-ABL signal transduction of those 
patients who start Imatinib in the early chronic, late 
chronic and accelerated phase of CML; 12%, 32%, and 
respectively 62% of CML patients in early chronic, late 
chronic and accelerated phase develop resistance 
mutations within 2 years from the first administration of 
the treatment. The resistance is based on multiple 
mechanisms, but the most important one is related to the 
mutations in BCR-ABL gene.  
The mutation analysis is vital to the selection of 
the proper therapeutic option for Imatinib resistant 
patients (Figure 4). The detection of new mutations 
suggests genetic instability during disease progression. 
The therapeutic options for Imatinib resistant patients 
consist either of an increased Imatinib dosage to 600mg 
or 800mg [5], or of the Imatinib replacing with the 2nd 
generation TKI – Dasatinib or Nilotinib [6]. Both 2nd 
generation TKI are recommended for CML patients 
resistant or intolerant to Imatinib. 
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Fig. 4 Graphical representation of BCR-ABL mutations and 
their sensitivity to different ITK. 
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Nilotinib is a selective tyrosine kinase inhibitor 
with an inhibiting effect thirty times higher than Imatinib. It 
is approved for the treatment of patients with CML in 
chronic or accelerated phase and for patients who are 
intolerant to Imatinib.    
Dasatinib is a highly dual potent Src\Abl 
inhibitor, active on BCR-ABL, SRC, c-kit, anti PDGFRβ. In 
vitro, its effect is 325 times more efficient than that of 
Imatinib. Nilotinib and Dasatinib have been found to be 
several folds more potent than Imatinib against cells 
expressing wild-type BCR/ABL and are active against all 
Imatinib resistant mutants tested, except for T3151.  
Dasatinib is more efficient in chronic phases in 
CML patients after the failure of Imatinib, than in 
accelerated phases or blast crises. Dasatinib versus 
Imatinib 800 mg daily in treatment of adults with CML 
chronic, accelerated or blast crises, with resistance to 
Imatinib in standard doses (400-600 mg daily), achieved a 
better cytogenetic and molecular response and a longer 
time of free disease survival. Dasatinib is currently 
indicated in a dosage of 100mg daily, having the same 
effects as doses of 70mg twice daily, but with less 
adverse reactions.  
The lack of crossover adverse reactions with 
Imatinib and the small number of adverse reactions, 
indicates Dasatinib in intolerance to Imatinib patients. The 
present indication of Dasatinib is in the treatment of CML 
patients with resistance or intolerance to Imatinib [7]. 
The new generations of TKI are still in trials, but 
with good promises especially from the TKI against T315I 
mutation. 
Conclusions 
Chronic myeloid leukemia represents the first 
malignancy with documented molecular etiology. Tyrosine 
kinase inhibitors opened a new era not only in the CML 
treatment, but also in the treatment of other malignant 
disorders. These drugs are a new hope for life in cancer 
patients. 
TKI dramatically changed the outcome of a 
malignant hematological disorder with an inexorable 
progression to acute leukemia, and it represents the first 
model of molecular target therapy. 
The tyrosine kinase inhibitors represent a new 
era not only in CML, but also in the therapy of other 
hematological or non-hematological neoplasms. They are 
a new hope of life for all the cancer patients. 
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